Estrella Immunopharma (ESLA) vs Quantum Biopharma (QNTM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Estrella Immunopharma (ESLA) has outperformed Quantum Biopharma (QNTM) over the past year, losing 67.9% versus a loss of 80.3%. Over five years, ESLA leads with a -95.8% price change compared with -96.7% for QNTM. Quantum Biopharma is the larger company by market cap ($20.0 million vs $18.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ESLA | QNTM |
|---|---|---|
| Share price | $0.4175 | $3.11 |
| Market cap | $18.16M | $20.00M |
| 1-day change | -0.43% | -1.11% |
| YTD return | -73.24% | -57.40% |
| 1-year return | -67.88% | -80.28% |
| 5-year return | -95.77% | -96.65% |
| EPS (TTM) | $-0.25 | $-4.98 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.15 | $16.36 |
| 52-week low | $0.361 | $2.07 |
| Distance from 52-week high | -86.75% | -80.99% |
| Analyst consensus | none | none |
| Avg. price target upside | +2774.25% | +294.53% |
| Average volume | 38.61K | 205.30K |
| Shares outstanding | 43.50M | 6.43M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ESLA has outperformed QNTM by 12.4 percentage points over the past year.
About Estrella Immunopharma
ESLA stock →Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
About Quantum Biopharma
QNTM stock →Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments.
Health Care · Biotechnology: Pharmaceutical Preparations
ESLA vs QNTM FAQ
Which is bigger, Estrella Immunopharma or Quantum Biopharma?
Quantum Biopharma (QNTM) is larger, with a market capitalization of $20.00M compared with $18.16M for Estrella Immunopharma (ESLA).
Which stock has performed better over the past year, ESLA or QNTM?
ESLA returned -67.88% over the past 12 months, compared with -80.28% for QNTM (price return, excluding dividends). Past performance does not predict future results.
Are Estrella Immunopharma and Quantum Biopharma in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Estrella Immunopharma and Biotechnology: Pharmaceutical Preparations for Quantum Biopharma.